Core Viewpoint - The article highlights the advancements and projects of Kasei (Taiyuan) Biomaterials Co., Ltd., particularly in the production of bio-based materials, showcasing significant growth in revenue and profit, as well as innovative product applications in the industry [2][5]. Group 1: Project Developments - Kasei is constructing a project with an annual capacity of 500,000 tons of bio-based hexamethylenediamine and 900,000 tons of bio-based polyamide, located in the Shanxi Synthetic Biology Industrial Ecological Park [2]. - The company currently has a series of bio-based dicarboxylic acids (DC10-DC18) with an annual capacity of 115,000 tons, and a bio-based sebacic acid project with an annual capacity of 40,000 tons that commenced production in 2022 [4]. - The bio-based hexamethylenediamine has an annual capacity of 50,000 tons, primarily used as a raw material for bio-based polyamide production [4]. Group 2: Financial Performance - In the first half of 2025, Kasei achieved a revenue of 1.671 billion yuan, representing a year-on-year increase of 15.68% [5]. - The net profit attributable to shareholders reached 309 million yuan, up 24.74% year-on-year, while the net profit after deducting non-recurring items was 296 million yuan, reflecting a growth of 23.67% [5]. Group 3: Research and Development - The company invested 123.2 million yuan in R&D in the first half of 2025, a 23.13% increase year-on-year, accounting for 7.37% of its revenue [4]. - Significant progress has been made in R&D projects related to green dicarboxylic acids, bio-based piperidine, bio-based long-chain polyamides, and high-value utilization of agricultural waste [4].

Core Points - The annual general meeting of Shanghai Cathay Biotech Co., Ltd. is scheduled for June 27, 2025, at 14:00, combining on-site and online voting methods [3][4] - The company reported a significant increase in revenue and net profit for 2024, with total revenue reaching CNY 2,957.91 million, a 39.91% increase year-on-year, and net profit attributable to shareholders amounting to CNY 488.96 million, a 33.41% increase [16][32] - The company plans to distribute a cash dividend of CNY 4.00 per 10 shares, totaling CNY 287.58 million, based on the audited net profit for 2024 [8][9] Meeting Procedures - Attendees must register and confirm their attendance before the meeting starts, and they are required to present their shareholder certificates to enter the venue [2][3] - The meeting will include the election of monitors and counters, the presentation of the independent directors' report, and the discussion of various proposals [4][6][11] Financial Performance - The company achieved a net profit of CNY 488.96 million in 2024, with a significant increase in net profit excluding non-recurring gains and losses, which rose by 51.60% to CNY 464.73 million [16][32] - The total assets of the company reached CNY 19.02 billion, reflecting a stable financial position [32] Strategic Developments - The company has successfully introduced CNY 5.915 billion in funding through a directed issuance of shares to enhance its business development [18] - A strategic cooperation agreement was signed with Hefei Municipal Government and China Merchants Innovation Technology Group to establish a synthetic biological materials industry cluster [18][28] Governance and Compliance - The board of directors and the supervisory board have actively fulfilled their responsibilities, ensuring compliance with relevant laws and regulations [19][25] - The company has maintained a high standard of information disclosure, achieving an A-level rating for its disclosure practices in the Shanghai Stock Exchange [23][26]